Article Sidebar
Main Article Content
Abstract
Background: Chronic misuse of potent topical corticosteroids can lead to irreversible visual loss, particularly in the pediatric population which exhibits a more aggressive trabecular meshwork remodeling response than adults. This case aims to delineate the silent progression of steroid-induced ocular hypertension in the absence of red-eye symptoms and emphasizes the critical pharmacokinetic risks of cutaneous-ocular absorption in children.
Case presentation: We report a catastrophic case of a 7-year-old male presenting with irreversible vision loss following six years of unsupervised, intermittent use of a combined Neomycin-Polymyxin B-Dexamethasone ointment for recurrent hordeolum. The cumulative exposure exceeded 125 mg of Dexamethasone. Examination revealed bilateral dense posterior subcapsular cataracts (PSC) and advanced glaucomatous optic neuropathy in left eye. Following sequential phacoaspiration, the left eye showed persistently elevated IOP (IOP elevated up to 59 mmHg) attributed to decompensated outflow facility. Management required Trabeculectomy with intraoperative 5-Fluorouracil (5 mg/0.1 mL). The high- responder phenotype in children involves rapid formation of Cross-Linked Actin Networks (CLANs) and MYOC gene upregulation. We discuss the double-hit mechanism where cataract extraction washes out hyposecretory factors, unmasking total trabecular blockage. The choice of 5-Fluorouracil over Mitomycin C is defended based on the safety profile regarding hypotony maculopathy in pediatric myopic eyes.
Conclusion: Dexamethasone carries a high risk of transcutaneous-ocular absorption in pediatric eye and eyelids. Regulatory reform reclassifying antibiotic-steroid combinations as non-repeatable prescriptions is imperative to prevent such preventable blindness.
Keywords
Article Details
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
